The object of this trial was to assess the comparative value of oxyphenbutazone as an alternative to prednisolone in the treatment of scleritis and episcleritis in patients in whom systemic treatment was indicated. In addition, it was hoped that some light could be shed on the diagnosis and aetiology of this group of diseases.
Inflammation of the episclera without involvement of the underlying sclera is termed episcleritis. Two types are generally recognized, simple episcleritis (including episcleritis periodica fugax) and nodular episcleritis (Fuchs, 1895; Schirmer, 1895; Duke-Elder, 1938) . Simple episcleritis is a disease of young or middle-aged adults characterized by diffuse congestion, with or without oedema of the episclera, accompanied by local pain and headache. Simple episcleritis often recurs at regular intervals and there may be a family history of the complaint. Although there may be no visible residium after each attack, this type of episcleritis is said to progress after many attacks to a scleritis or sclerokeratitis (Duke-Elder, 1938 ).
Nodules can occur in the episclera in gout, tuberculosis, syphilis, zoster, and other conditions, including metastatic pyogenic infections. Most frequently, no aetiological factor can be found and the condition is then described as nodular episcleritis, a recurrent disease found especially in the middle-aged or elderly (Duke-Elder, 1938) . It is characterized by the appearance in the episclera of nodules surrounded by haloes of injected episcleral vessels, and occasionally the overlying conjunctival vessels are injected. Nodular episcleritis is usually a benign condition which does not progress to scleritis. Scleritis may have nodules associated with it but this does not mean that the condition started as a nodular episcleritis (Swan, 1951) .
Scleritis is a severe disease and can ultimately be blinding. It causes severe pain and headache; many eyes are removed for intractable pain. It is usually subdivided, according to the site involved, into sclerokeratitis, anterior and posterior scleritis. If the inflammation is very severe with pitting oedema of the overlying episclera, it is termed brawny scleritis. It is almost always accompanied by an anterior or posterior uveitis. It is most often associated with rheumatoid arthritis, polyarteritis nodosa, or Wegener's granulomatosis. Rheumatic nodules in the sclera may rarely cause holes to appear in the sclera without the surrounding signs of inflammation. The condition is then known as scleromalacia perforans (van der Hoeve, 1934) . In this trial, scleritis was divided into mild, moderate, or severe, regardless *of position or particular manifestation. Before the introduction of steroids the treatment of episcleritis and scleritis was regarded as difficult and unrewarding. There is almost universal agreement on the value of local steroids in the suppression of the inflammation in episcleritis, particularly during the first attack, but the situation is far less satisfactory in recurrent episcleritis and in scleritis where the disease often progresses in spite of local therapy.
Organization of the Trial The difficulty of assessing the prognosis in episcleritis led us to include all cases referred in which the condition had deteriorated or recurred in spite of previous local steroid therapy. It was reasonable, therefore, to use drugs which were known to have occasional unpleasant side-effects.
The two groups of patients, the oxyphenbutazone-treated group (Group 0) and the prednisolone-treated group (Group P) were balanced on entry to the trial by the method of stratified randomization according to age, length of history, and severity of disease. Two age groups (under 45 years and 45 years and over), two length-of-history groups (under one month, one month and over), and three severity groups (simple episcleritis, nodular episcleritis, and scleritis) were used, giving twelve possible sub-groups. Previous treatment was disregarded, except that patients who had had subconjunctival injections of steroids, or systemic steroids, pyrazoles, or aspirin (over gr. 30 a day) during the past 3 months, were excluded. Patients with contraindications to either drug were, of course, excluded. Local steroids were not used during the trial.
Assessment of Severity of Disease and Response to Treatment
The following factors were noted when the patients entered the trial: (1) Pain; (2) flare; (3) keratic precipitates; (4) cells; (5) episcleral injection; (6) conjunctival injection; (7) keratitis (type); (8) keratitis (degree); (9) scleral thinning; (10) nodules. Table I (opposite) summarizes the factors consider6d in assessing the original category and the response to treatment. The trial was planned to last 56 days; the patients were seen weekly for 4 weeks and then fortnightly.
Treatment
Tablets of prednisolone 5 mg. were manufactured to match exactly tablets of oxyphenbutazone 100 mg. In each group the dosage scheme was as given in Table II  (opposite) .
At the beginning of treatment each patient was given a bottle which contained enough tablets to last the duration of the treatment, and the selection of treatmentoxyphenbutazone or prednisolone-was arranged by use of random number tables. The observation was a double-blind throughout; the key was held by the pharmacist and referred to only in cases of emergency. At the outset it was hoped to include sixty patients in the trial This dosage was selected because it had been found in a preliminary study to give adequate suppressive response. (Bywaters and Holloway, 1964) . There was no overt clinical evidence of gout in any of these cases.
The three with positive tests for syphilis were referred to the special department, but continued in the trial; one was later found to have false positives.
Of the patients with positive latex or Waaler-Rose tests, only two had associated systemic disease: one Henoch-Schonlein purpura and one rheumatoid arthritis.
Results of the Trial Assessment of the Similarity of the Two Treatment Groups at the Start of the Trial Entry to the trial ceased when the sixtieth person had been admitted, but one was later excluded because of doubtful diagnosis, leaving 30 persons who were given oxyphenbutazone and 29 given prednisolone. Detailed statistical examination of the data on sex, age, severity, and duration of the disease was made. This showed the two groups to be similar, regardless of whether the figures were based on persons or eyes affected. Though the oxyphenbutazone group had a female preponderance (63 per cent. to 55 per cent.) this was not statistically significant (throughout this report, statistical significance is that P < 005). The mean age of the oxyphenbutazone group was 46-9 ± 2-52 years, and that of the prednisolone group 473 ± 2-61 years, and the distributions were similar.
The three diagnostic categories were present in similar proportions in both treatment groups, except that there were three patients with scleritis in the oxyphenbutazone group and only one in the prednisolone group, the latter being later excluded from analysis because of non-attendance, suggesting that the oxyphenbutazone group was slightly more severely affected.
Both eyes were affected at some period of the trial in five patients of the oxyphenbutazone group, and ten of the prednisolone group. In making the clinical assessments for these patients, each eye was graded separately and the analysis which follows is based on the number of eyes rather than on the number of persons affected. 
TREATMENT OF EPISCLERITIS-SCLERITIS
Thus, the oxyphenbutazone group comprised 35 eyes and the prednisolone group 39 eyes, rather than 30 and 29 persons respectively. This did not materially alter the sex and age distributions, nor was the difference in the distribution of length of history affected.
Initial Assessment
The signs and symptoms recorded at the first and subsequent assessments (Days 0, 7, 14, 21, 28, 42, and 56) are shown in Table I . As already indicated, arrangements were made for the two treatment groups to be balanced for the factors of age, severity of disease, and length of history. Before comparing the results in the two groups it was important to show that they were similar in respect of the presenting symptoms and signs. Four main points emerged:
(1) As the majority of the eyes did not have any flare, keratic precipitates, cells, keratitis, or scleral thinning, there was little room for improvement on either drug. (2) The distribution of the pain in the two groups was significantly dissimilar. In 45 per cent. of the oxyphenbutazone group it was either absent or only mild and intermittent, as against 38 per cent. of the prednisolone group.
(3) On the small numbers involved it was not possible to demonstrate significant differences as regards episcleral and conjunctival injection, but the precentages suggest that the two groups could hardly be termed alike as regards these characteristics (e.g. episcleral injection was present in 100 per cent. of the oxyphenbutazone group and in 89 per cent. of the prednisolone group).
(4) The mean nodule scores at the start of the trial were 3 52 + 0 58 for the oxyphenbutazone group and 3-24 + 0 55 for the prednisolone group-very similar.
Patients withdrawn from the Trial
Patients who, for any reason, were not assessed up to the 56th day of the trial were regarded as withdrawals. An occasional failure to attend for assessment on any day but the 56th was ignored in analysing the data, the grades on such single days of the non-attendance being regarded as unchanged from the previous assessment.
Eight patients from the oxyphenbutazone group (all with only one eye affected) and seven from the prednisolone group (one with both eyes affected) were withdrawn. The reasons for withdrawal, including breaking the code because of failure to respond to treatment, are summarized in Table IV . Table V shows the side-effects suffered by the patients and the abnormalities which were observed during the course of the trial. The effects which we believe to be either related or unrelated to the drug treatment are tabulated separately and the results based on our own experience and reports of other observers. Our conclusions group.bmj.com on June 21, 2017 -Published by http://bjo.bmj.com/ Downloaded from TREATMENT OF EPISCLERITIS-SCLERITIS are that there were five patients in Group 0 and six in Group P with side effects due to the drug, of which, as seen from the previous section, one in the oxyphenbutazone group and one in the prednisolone group were withdrawn from the trial. It is obvious from this Table that the difference in the number of side-effects is very slight. However, the types of side-effect in each group are quite dissimilar, apart from gastric symptoms.
Comparison of the Two Methods of Treatment Pain
Resolution of Pain.-The number of eyes free from pain is shown graphically in Fig. 1 . It can be seen that there is little difference between the two groups; the initial advantage in the prednisolone group was maintained for 21 days, but after this the oxyphenbutazone group had less pain.
Inprovement in Pain.-The above method ignores improvement or deterioration. The graphs in Fig. 2 (a and b) show this as a percentage of eyes improving or deteriorating as compared with the previous assessment. There is very little difference in improvement rates (Fig. 2a) , though a marked deterioration is shown in the prednisolone group between days 21 and 42 (Fig. 2b) . Similarly, an eye giving severe and constant pain can improve much more than one with only slight and occasional pain. The possible degree of improvement on each assessment day was therefore calculated, i.e. each eye was graded numerically, showing how many grades it could improve. The total percentage improvement in each group was compared with that which was possible. Similarly, an eye giving severe and constant pain could not become more painful, whereas an eye with little pain could get much worse. Similar calculations were therefore made for deterioration in relation to possible deterioration.
The results of these calculations are shown in Fig. 3 . Fig. 3b Fig. 4 (opposite) . The groups improved in parallel for 2 weeks. In the third week the prednisolone group improved markedly and then deteriorated rapidly, while the oxyphenbutazone group showed maintenance or steady improvement from the third week onwards. Figs 5 (a and b) .
These show similar trends, with improvement a little in favour of the prednisolone group in the third week, but marked statistically significant improvement in the oxyphenbutazone group in the last weeks of the trial when compared with the prednisolone group (Fig. 5a) .
The deterioration in the steroid group was marked during the fourth week of the trial and significantly greater than that in the oxyphenbutazone group (Fig. Sb) .
Conjunctival Injection
Resolution of Conjunctival Injection.-This is illustrated in Fig. 6 (overleaf). In the first week the oxyphenbutazone group did slightly better and during the second and third weeks the prednisolone group improved more, but after this the differences were slight. Improvement in Conjunctival Injection in relation to Possible Improvement.-During the third week the greater improvement in the prednisolone group was statistically significant but there was marked deterioration in this group between the fourth and sixth weeks, these differences also being statistically significant (Figs 7a and b 
Nodules
Nodules were graded numerically, depending on size and number, and the total for each group was calculated for each assessment day. Fig. 8 shows the mean score for nodules at each assessment day as a percentage of the score on Day 0. The graph shows the more marked regression of nodules during the first 7 days in the prednisolone group, but the slower effect of the oxyphenbutazone was more complete and persisted, while the prednisolone group retrogressed during the last weeks of the trial. The differences between the two groups during the last weeks of the trial are statistically significant. 
Combined Scores for all Symptoms and Signs except Nodules
All symptoms and signs (except scleral thinning and the quality of the keratitis) were given a numerical code and the means for each assessment day calculated. The results are shown graphically in Fig. 9 . The groups can be seen to be very similar for 3 weeks, when the prednisolone group began to deteriorate while the oxyphenbutazone group continued to improve. The differences were statistically significant at Days 42 and 56. Total Scores for all Symptoms and Signs, including Nodules Fig. 10 , which is very similar to Fig. 9 , shows the steady improvement in both groups for 3 weeks, and thereafter the deterioration in the prednisolone group with continued improvement in the oxyphenbutazone group, producing statistically significant differences at Days 42 and 56. Discussion The initial assessment shows that the two groups were comparable in that they were similar as regards sex, age, general severity; and length of history, but not precisely alike as regards the severity of individual symptoms. Allowance has been made for these minor differences by the method adopted for comparing subsequent progress.
Analysis shows that the improvement in the two treatment groups was roughly parallel until Day 21. Some symptoms showed greater improvement on prednisolone, but not to a statistically significant degree except for conjunctival injection during the third week. After Day 21 the oxyphenbutazone group continued to improve rapidly in regard to pain, episcleral injection, and conjunctival injection, but the prednisolone group deteriorated after Day 21, particularly between Days 28 and 42. Some symptoms, therefore, in the oxyphenbutazone group improved to a significantly greater extent than in the prednisolone group during the last month of the trial.
As described on p. 468, there was no marked difference in the occurrence of sideeffects between the two groups. This was to a certain extent due to the fact that patients with contraindications to the drugs were excluded. There were no sideeffects noted which had not previously been reported and none .of really serious significance. From this it may be concluded that neither preparation had any marked advantage in this respect during the investigation.
A fixed-dosage double-blind trial of this nature always suffers in that it is difficult to know whether the drugs are being used to their best advantage. In this instance, it is possible, on the one hand, that the steroids may have been withdrawn too soon or too rapidly; on the other hand, it is possible that steroid-dependence may have been avoided by this short period of administration. Oxyphenbutazone has a halflife of about 3 days, but this cannot explain the differences,shown between the two groups. By extension of the trial we hope to obtain answers to these questions.
As episcleritis has a marked tendency to recur and, perhaps in some cases, to progress to scleritis, a long-term follow-up has been arranged to show whether the apparent sustained improvement of those patients given oxyphenbutazone continued over a long period. Summary (1) A double-blind controlled study was made into the effects of treatment of 59 patients with oxyphenbutazone (Tanderil) and prednisolone in episcleritis and scleritis. Oxyphenbutazone has been shown to be effective in the treatment of episcleritis. Too few cases of scleritis were studied to allow firm conclusions to be drawn.
(2) Oxyphenbutazone (600 mg./day) had less effect than prednisolone (30 mg./day) during the initial stages, but 3 weeks' treatment with oxyphenbutazone (400 mg./day) had a very similar effect to 3 weeks of prednisolone (20 mg./day). With oxyphenbutazone the improvement produced was maintained, whereas the patients receiving prednisolone tended to deteriorate as treatment was withdrawn.
(3) No single aetiological factor was present in all the cases studied in this trial. The commonest associated condition was active rheumatic disease.
(4) Two patients receiving oxyphenbutazone and one patient receiving prednisolone were withdrawn from the trial because of side-effects attributable to the drugs.
APPENDIX DETAILS OF RESULTS Comparison of Progress in the Two Treatment Groups
Pain.-The distribution of the various degrees of pain at the onset of the trial is given in Table VI . Because the two treatment groups differed at the onset of the trial, direct comparison of distribution as the trial progressed is not justifiable.
Resolution of Pain.-This is shown graphically in Fig. 1 This method of comparison deals only with the patients who were pain-free at each assessment. It does not take into account those who had a reduction in pain but were not pain-free.
Percentage of Eyes improving or becoming Worse.-This is shown graphically in Fig. 2 constructed from figures given in Table VIII (overleaf). Improvement in Pain.-It is obvious that a pain-free eye cannot improve in this respect, though'it can deteriorate four grades to severe and constant pain. Similarly, an eye with constant severe pain cannot become more painful, though it could improve four grades to pain-free. A method was devised to differentiate, for example, between the eye which improved from "severe constant" pain to "mild intermittent" pain and the eye which improved from "mild intermittent" pain to no pain.
This was done by expressing the actual number of grades improved by each treatment group as percentages of the possible number of grades of improvement, as shown, for example, in the oxyphenbutazone group at Day 0: 2 eyes in category O could improve O categories each= 0 13 eyes in category I could improve I categories each 13 Possible 11 eyes in category 2 could improve 2 categories each =22
Total 5 eyes in category 3 could improve 3 categories each =15 58 2 eyes in category 4 could improve 4 categories each = 8 It was found that the actual number of grades which the eyes improved was 42, or 72 per cent. of the possible number. Similar calculations were made for both treatment groups at each day of assessment. These were repeated for downgrading. The differences between the percentages in the two groups were tested for statistical significance.
The only significant difference was the excess of downgrading in the prednisolone group between Days 21 and 28. During this week the actual number of grades retrogressed was 13 per cent. of the possible number as against only 4 per cent. in the oxyphenbutazone group. The trend of the upgrading percentages is of interest, since it suggests that up to Day 21 the prednisolone group had the advantage, but subsequently the oxyphenbutazone group showed greater improvement, while after Day 21 the prednisolone group showed greater deterioration. These figures are illustrated graphically in Fig. 3 (a and b) . (58) 56 (18) 31 (13) 71 (7) 50 (6) 43 (7) Prednisolone 76 (59) 85 (16) 33 (12) 50 (16) 41 (7) 39 ( 
Improvement during the First 7 Days
For the first period of the trial only (Day 0 to Day 7), the number of grades of improvement or deterioration was examined in still greater detail (Table X) . This examination showed that it was possible for:
(a) 7 eyes in the 0 group to improve 3 grades, and that 4 did so, i.e. 57 per cent. compared with 60 per cent. in the P group.
(b) 18 eyes in the 0 group to improve 2 or more grades and that 13 did so, i.e. 72 per cent. compared with 61 per cent. in the P group.
(c) 31 eyes in the 0 group to improve 1 grade or more and that 25 did so, i.e. 81 per cent. compared with 93 per cent. in the P group.
The last difference is significant. Fig. 4 . Fig. 6 , prepared from the figures in Table XIII. On entry to the trial the prednisolone group was less severely affected, 11 per cent. having conjunctival injection, but by Day 7 both had the same proportion (76 per cent,) affected. From Day 7 to Day 28 the prednisolone group improved more quickly than the oxyphenbutazone group, but on Days 42 and 56, the percentage with no quadrant affected was the same in the two groups.
Improvement in Conjunctival Injection.-When this criterion was examined in more detail (Fig. 7 (a and b) and Table XIV ) and the total amount of upgrading measured as a percentage of possible upgrading, the prednisolone group was better up to Day 21, significantly so at Day 21, but after Day 28 the oxyphenbutazone group did better. Similarly, by Days 28 and 42, the prednisolone group had deteriorated significantly as compared with the oxyphenbutazone group. Figures in brackets are the number of possible grades.
Thus one may conclude that as regards conjunctival injection the prednisolone group was significantly better up to Day 21, but the group showed significant deterioration during and after withdrawal of treatment. 
12-1).
J This is significant and confirms the advantage to the prednisolone group in this early period of the trial.
Nodule Scores (Fig. 4) As mentioned earlier each nodule scored 1 if just definite, 2 if fairly obvious, 6 if very obvious, and 10 if large and confluent with neighbouring nodules. It was thus possible to calculate mean scores for each treatment group at every assessment. These means are shown in Table XV , and Fig. 8 shows these means as a percentage of the mean score at Day 0. The mean nodule score of the oxyphenbutazone group was higher (but not significantly so) up to Day 28. Subsequently the score in this group was nil while that of the prednisolone group increased, so that on Day 42 the mean of the prednisolone group was significantly higher, and remained higher at Day 56. The mean score of the prednisolone group fell more rapidly than the oxyphenbutazone group until Day 28 and then rose. This conforms with the pattern of the other symptoms and signs.
Since patients who scored nil for nodules at the start of the trial could not improve, the means were recalculated when such patients were excluded. The deductions made were entirely unchanged, the significant advantage to the oxyphenbutazone group at Day 42 persisted, and the trend of the means remained similar for both groups.
